Literature DB >> 14613960

Pharmacological indices in antibiotic therapy.

Antina Barger1, Christine Fuhst, Bernd Wiedemann.   

Abstract

After 60 years of antibiotic treatment, attempts to rationalize it have culminated in the use of pharmacological indices. These indices facilitate comparison of the activity of different antibiotics and serve as a sound basis for antibiotic dosing. Pharmacokinetic parameters (e.g. AUC, Cmax) and pharmacodynamic parameters (mostly MIC) are used for this purpose. For the so-called concentration-dependent antibiotics, the pharmacological indices AUC/MIC and Cmax/MIC are used, whereas for time-dependent antibiotics, the pharmacological index T>MIC is used. Some authors believe that the index AUC/MIC can be used as a universal index, but, not all experts accept this generalization. As the various pharmacological indices have been defined inconsistently in the literature, the International Society for Anti-Infective Pharmacology (ISAP) has published a paper on the terminology of pharmacokinetic and pharmacodynamic parameters and the pharmacological indices. This paper will help to ensure uniform use of terminology. In addition, we point out that the use of pharmacological indices should consider the differences in pharmacokinetics (patient characteristics and localization of the infection) and the differences in pharmacodynamics of antibiotics (beyond MICs) with different pathogens (e.g. Gram-positive and Gram-negative).

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14613960     DOI: 10.1093/jac/dkg482

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  14 in total

Review 1.  The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Authors:  T Tängdén; V Ramos Martín; T W Felton; E I Nielsen; S Marchand; R J Brüggemann; J B Bulitta; M Bassetti; U Theuretzbacher; B T Tsuji; D W Wareham; L E Friberg; J J De Waele; V H Tam; Jason A Roberts
Journal:  Intensive Care Med       Date:  2017-04-13       Impact factor: 17.440

2.  A general model-based design of experiments approach to achieve practical identifiability of pharmacokinetic and pharmacodynamic models.

Authors:  Federico Galvanin; Carlo C Ballan; Massimiliano Barolo; Fabrizio Bezzo
Journal:  J Pharmacokinet Pharmacodyn       Date:  2013-06-04       Impact factor: 2.745

Review 3.  A long journey from minimum inhibitory concentration testing to clinically predictive breakpoints: deterministic and probabilistic approaches in deriving breakpoints.

Authors:  A Dalhoff; P G Ambrose; J W Mouton
Journal:  Infection       Date:  2009-07-23       Impact factor: 3.553

4.  Intracellular time course, pharmacokinetics, and biodistribution of isoniazid and rifabutin following pulmonary delivery of inhalable microparticles to mice.

Authors:  Rahul Kumar Verma; Jatinder Kaur; Kaushlendra Kumar; Awadh Bihari Yadav; Amit Misra
Journal:  Antimicrob Agents Chemother       Date:  2008-06-30       Impact factor: 5.191

Review 5.  How to Treat Sepsis in the Background of Resistance?: Role of Pharmacodynamics / Pharmacokinetics in Treating Sepsis.

Authors:  Mohit Agrawal; Ashok Rattan
Journal:  Indian J Pediatr       Date:  2020-01-14       Impact factor: 1.967

6.  Azithromycin enhances phagocytic killing of Aggregatibacter actinomycetemcomitans Y4 by human neutrophils.

Authors:  Pin-Chuang Lai; Mark R Schibler; John D Walters
Journal:  J Periodontol       Date:  2015-01       Impact factor: 6.993

7.  Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model.

Authors:  Kerry L LaPlante; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2004-12       Impact factor: 5.191

8.  Activity of linezolid in an in vitro pharmacokinetic-pharmacodynamic model using different dosages and Staphylococcus aureus and Enterococcus faecalis strains with and without a hypermutator phenotype.

Authors:  Boubakar B Ba; Corinne Arpin; Branly Bikie Bi Nso; Véronique Dubois; Marie-Claude Saux; Claudine Quentin
Journal:  Antimicrob Agents Chemother       Date:  2010-01-25       Impact factor: 5.191

9.  Pharmacokinetics of acyclovir after intravenous infusion of acyclovir and after oral administration of acyclovir and its prodrug valacyclovir in healthy adult horses.

Authors:  B Garré; K Shebany; A Gryspeerdt; K Baert; K van der Meulen; H Nauwynck; P Deprez; P De Backer; S Croubels
Journal:  Antimicrob Agents Chemother       Date:  2007-09-10       Impact factor: 5.191

10.  Antimicrobial breakpoint estimation accounting for variability in pharmacokinetics.

Authors:  Goue Denis Gohore Bi; Jun Li; Fahima Nekka
Journal:  Theor Biol Med Model       Date:  2009-06-26       Impact factor: 2.432

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.